FDA Advisory Panel Endorses Grail's Galleri Test

An FDA advisory committee voted 7-2, with one abstention, that the benefits of Grail's multi-cancer blood test outweigh its risks, despite ongoing skepticism from some experts regarding its effectiveness in reducing late-stage cancer diagnoses.

The top 3

  1. Vote Breakdown: Benefits vs. Risks: The 10-person panel voted 7-2 in favor of the benefit-risk profile, 6-4 in support of effectiveness, and unanimously (10-0) confirmed the test's safety. Grail
  2. Clinical Evidence: PATHFINDER 2 Study: The application is supported by data from the PATHFINDER 2 study, which enrolled 35,878 participants, and data from the NHS-Galleri trial involving over 70,000 individuals.
  3. Key Criticisms: Late-Stage Detection Gap: Critics point to the NHS-Galleri trial results, which showed no statistically significant reduction in stage 3 and 4 cancer diagnoses among subjects using the test.

Sources

Open the full topic